Eisai Asks Appeals Court To Order DEA To Make Rule, Allow New Epilepsy Drug's Sale

Eisai Asks Appeals Court To Order DEA To Make Rule, Allow New Epilepsy Drug's Sale

WASHINGTON, D.C. - Japanese drug maker Eisai Inc. on Aug. 19 petitioned the District of Columbia federal appeals court for a writ of mandamus to force the U.S. Drug Enforcement Agency (DEA) to issue a rule that will allow the company to move forward with the marketing of its approved new epilepsy drug (In re Eisai Incorporated, No. 13-1243, D.C. Cir.).

Find full version on lexis Advance®
Access this news story on lexis.com®